Hutchison-China Meditech (和黄医药) H-Share Listing: MNC Partnerships Endorsed Its R&D Capabilities
Hutchison-China Meditech, China-based AIM and NASDAQ dual listed pharmaceutical company, is seeking to raise up to USD 500 million via a Hong Kong...
675 Views
2018 HK-Connect SouthBound In a Nutshell
Since autumn of 2014, the HK-Shanghai Connect, and later the HK-Shenzhen Connect mechanisms have provided means for mainland investors to buy Hong...
701 Views
WuXi AppTech IPO Update: Figuring Out the Right AH Premium
WuXi AppTec Co. Ltd. (WUXI HK) is a leading global pharmaceutical R&D outsourcing service provider and the largest in Asia by revenue in 2017....
722 Views
China Medical Devices: "Two-Invoice" Is Coming
Sinopharm Group Co H (1099 HK) 's pending acquisition of a majority interest in China National Scientific Instruments and Materials Co. Ltd....
633 Views
China Drug Distribution: More "Two Invoice" Changes
The restructuring of China's drug distribution industry continues with Baiyunshan Phrmcl Hldgs Co Ltd (874 HK)'s pending buyout of Walgreens Boots...
428 Views